PHOTODYNAMIC THERAPY MARKET ANALYSIS

Global photodynamic therapy market is estimated to be valued at US$ 4.51 Bn in 2023. Projections indicated a promising trajectory, with an anticipated compound annual growth rate (CAGR) of 8.6% from 2023 through 2030. By 2030, the market is poised to expand significantly, nearing the valuation of nearly US$ 8.02 Bn.

Photodynamic therapy is a medical intervention that employs a blend of photosensitive drugs and light to eradicate cancer cells and address diverse medical ailments. Multiple determinants influenced the dimensions of the market. These factors encompassed technological advancements, the prevalence of conditions amenable to PDT such as cancer, regulatory endorsements, and overarching trends in healthcare.

A number of catalysts drove the PDT market's growth. Escalating incidences of skin cancer and other malignancies, coupled with escalating demand for procedures characterized by minimal invasiveness are expected to drive the market growth. Furthermore, the heightened adoption of PDT for addressing pre-cancerous conditions further fueled the market growth.

Global Photodynamic Therapy Market- Regional Insights

The geographical distribution and expansion of the photodynamic therapy (PDT) market can differ based on various factors encompassing healthcare infrastructure, regulatory context, technological advancements, disease prevalence suitable for PDT treatment, and economic circumstances across global regions. In general, regions endowed with robust healthcare systems, formidable research and development capabilities, and a higher incidence of PDT-applicable conditions, notably cancer, are likely to exhibit substantial growth in this sector.

• North America: Anticipated to command the most significant share of the PDT market during the projected period, North America's prominence stems from its early adoption of PDT practices and a substantial presence of market participants. Notably, the U.S. constitutes the most extensive PDT market within North America., North America has claimed the largest revenue portion in the global PDT market due to widespread integration of advanced therapies, substantial healthcare expenditure, rising cancer prevalence, and favorable reimbursement structures fostering PDT adoption. North America accounts for approximately 30.0% of the overall market share.
• Europe: Projected to rank as the second-largest PDT market during the forecast timeframe, Europe's position derives from the escalating incidence of skin disorders and cancer across the region. Key players within this market include Germany, France, and the U.K. Europe held the runner-up spot in the PDT market after North America due to robust healthcare infrastructure, a cluster of leading medical technology firms, and increasing authorization of PDT for diverse indications. Europe commands around 25.3% of the total market share.
• Asia Pacific: Poised to emerge as the fastest-growing PDT market throughout the projected period, Asia Pacific's ascent can be attributed to the mounting awareness regarding PDT and the surging prevalence of skin disorders and cancer in the region. Leading markets within Asia Pacific encompass China, India, and Japan. Asia Pacific market has displayed the highest growth trajectory. Factors propelling this growth include expanded healthcare accessibility, a substantial patient pool, and augmented healthcare investments, particularly in China and India. Asia Pacific contributes to approximately 20.4% of the overall market share.

Figure 1. Global Photodynamic Therapy Market Share (%), By Region, 2023

To learn more about this report, request sample copy

Analyst View-

Global photodynamic therapy market is driven by rising prevalence of various types of cancers worldwide. PDT provides a non-invasive alternative to cancers affecting the skin, esophagus, lungs, and other organs. It reduces the need for surgery in several cases. Growing geriatric population who are more prone to develop cancer also contributes to market growth. However, limited drug availability, high cost of therapy and strict regulatory approvals are some challenges restraining the market growth. Moreover, ongoing research into expanding PDT applications to treat conditions like acne, pigmented lesions, and age-related macular degeneration (AMD) presents lucrative opportunities. Market players are also developing advanced light devices and pharmaceutical formulations to overcome existing limitations.

Global Photodynamic Therapy Market- Drivers

• Increasing Incidence of Cancer and Skin Disorders: Rising prevalence of cancer, particularly skin cancers like basal cell carcinoma and squamous cell carcinoma, boosts demand for effective treatment options like PDT. As cancer rates continue to rise globally, For instance, in February 2022, according to the World Health Organization's (WHO), cancer accounted for around 10 million deaths worldwide, or roughly one in six fatalities in 2020. Thus, the increasing prevalence of cancer cases across the globe is expected to boost demand for photosensitizer drugs, thereby, accelerating the market growth. 
• Minimally Invasive Treatment Demand: PDT is considered a minimally invasive treatment option as compared to traditional surgery and chemotherapy. As patients seek less invasive approaches that offer quicker recovery times and reduced side effects, the demand for PDT increases.
• Advancements in Technology: Ongoing technological advancements in light sources, photosensitive drugs, and imaging techniques have improved the precision and effectiveness of PDT. These advancements attract both patients and healthcare providers, contributing to market growth.
• Favorable Regulatory Approvals: Regulatory agencies around the world had been granting approvals for various indications of PDT, such as skin cancers, pre-cancerous conditions, and certain non-oncological applications. These approvals expand the market potential and encourage healthcare providers to adopt PDT as a treatment option. For instance, in September 2021, Soligenix, Inc., a biopharmaceutical company, announced that the Office of Orphan Products Development of the U.S. Food and Drug Administration had granted orphan drug designation to the active ingredient hypericin for the treatment of T-cell lymphoma, extending the target population beyond cutaneous T-cell lymphoma.

Global Photodynamic Therapy Market- Opportunities

• Personalized Treatment Approaches: Personalized medicine and molecular diagnostics advances may enable PDT therapies to be customized to the unique profiles of every patient. This approach enhances treatment outcomes and patient satisfaction, and it presents an opportunity for precision medicine to be integrated into PDT protocols.
• Collaboration with Pharmaceutical Companies: Collaboration with pharmaceutical companies can lead to the development of innovative photosensitive drugs that enhance the efficacy of PDT. Collaborations can also facilitate the incorporation of PDT into combination therapies, thereby expanding its potential applications. For instance, on February 16, 2023, Lumeda Inc, a clinical-stage medical technology company that focuses on improving treatment outcomes of patients with lung cancer, and photonamic GmbH & Co KG, a pharmaceutical company involved in the development of 5-aminolevulinic acid (5-ALA) in various applications as a precursor for the photosensitizer PpIX, announced their commitment to collaborate on a Phase I-II clinical study to evaluate the safety and efficacy of Photodynamic Therapy (PDT) with 5-ALA as an adjuvant in combination with Immune Checkpoint Inhibitors (ICIs) to prime the immune system in the treatment of lung cancer patients.
• Advancements in Imaging Techniques: Improved imaging technologies can enable better visualization of targeted tissues, enhancing the accuracy of PDT treatments. Innovations in imaging methods, such as fluorescence imaging and molecular imaging, can create opportunities for more effective treatment planning and monitoring.
• Telemedicine and Remote Consultations: The integration of telemedicine and remote consultations can facilitate patient access to PDT expertise and guidance, particularly in areas with limited healthcare infrastructure. This approach can broaden the reach of PDT treatments to underserved populations.

Global Photodynamic Therapy Market- Trends

• Combination Therapies: Combination therapies involving PDT are gaining traction. The synergistic effects of combining PDT with other treatment modalities, such as immunotherapy or targeted therapies, show potential for enhanced treatment efficacy, particularly in challenging cases like resistant cancers.
• Product Launches: Increasing new product launches in the market is expected to drive the market growth over the forecast period. For instance, in July 2022, Biolitec Pharma Ltd., a medical technology company, introduced the latest generation laser device named ELVeS Radial Laser System. The device offers advanced treatment options for various medical conditions including cancer, benign prostatic hyperplasia, and varicose veins, and thus, showcasing the continuous innovation in photodynamic therapy technologies.
• Minimally Invasive and Outpatient Procedures: The trend towards minimally invasive and outpatient procedures is boosting demand for PDT. Patients seek treatments that offer shorter recovery times and reduced hospital stays, aligning with PDT's characteristics.
• Advancements in Photosensitizers: Research efforts are focusing on developing more efficient and selective photosensitizers. Novel photosensitizers with improved pharmacokinetics, enhanced selectivity for cancer cells, and reduced side effects are being explored.

Global Photodynamic Therapy Market- Restraints

• Limited Awareness and Education: Lack of awareness among both patients and healthcare providers about PDT and its potential benefits can hinder its adoption. Education campaigns and training initiatives are needed to address this limitation.
• High Treatment Costs: PDT can be cost-intensive, involving specialized equipment, photosensitive drugs, and skilled personnel. High treatment costs can deter both patients and healthcare facilities from adopting PDT, particularly in regions with limited healthcare budgets.
• Complex Treatment Protocols: PDT involves multiple steps, including photosensitizer administration, light exposure, and post-treatment care. Complex protocols can require specialized training for healthcare professionals and may affect treatment accessibility.

Figure 2. Global Photodynamic Therapy Market Share (%), By End User, 2023

To learn more about this report, request sample copy

Global Photodynamic Therapy Market- Recent Developments

New Product Approvals

• On July 5, 2023, the FDA had granted orphan drug designation to padeliporfin vascular targeted photodynamic therapy (VTP) for use as a potential therapeutic option in patients with locally advanced pancreatic cancer
• On February 1, 2023, Bausch + Lomb Corporation, a leading global eye health company dedicated to help people see better to live better, and Modulight Corporation, a biomedical laser company, announced that the U.S. Food and Drug Administration (FDA) had approved the ML6710i photodynamic laser for equivalent use with Bausch + Lomb’s VISUDYNE (verteporfin for injection) photodynamic therapy (PDT) for the treatment of patients with predominantly classic subfoveal choroidal neovascularization, or the creation of abnormal choroidal blood vessels, due to Age-related Macular Degeneration (AMD).
• On January 12, 2023, Biofrontera AG, an international biopharmaceutical company, announced that its wholly owned subsidiary Biofrontera Bioscience GmbH had received a notice of allowance for the application "Photodynamic therapy comprising two light exposures at different wavelengths" (US Appl. No. 17/269,816) by the U.S. patent office USPTO. This patent protects a number of innovations relating a new illumination method to treat dermatological skin diseases with Photodynamic Therapy (PDT).

Acquisition and Partnerships

• On August 13, 2023, ImPact Biotech, a leader in photodynamic therapy, announced an agreement with Maastricht University to collaborate in research focused on eye treatment to arrest the progression of the severe eye disease Pathological Myopia, also known as Myopic Macular Degeneration (MMD). The project will use ImPact’s Padeliporfin Vascular targeted photodynamic therapy (VTP) therapy platform.
• In September 2022, Quest PharmaTech Inc., a biotech company, announced the sale of its ownership interest in Bioceltran Co., Ltd. for a sum of US$ 300, 0000, together with the return and cancellation of the technology license for Photodynamic Therapy (PDT).
• In January 2021, Olympus Corporation, a manufacturer of optics and reprography products, announced that it had entered into an agreement to acquire Quest Photonic Devices B.V., a medical device company, for up to US$ 52.7million including milestone payments to strengthen its surgical endoscopy capabilities.

Top companies in Global Photodynamic Therapy Market

• Gladerma S.A.
• Sun Pharmaceutical Industries Ltd.
• Biofrontera
• Novartis AG
• Valeant Pharmaceuticals International, Inc.
• Quest Pharmatech, Inc.
• Hologic, Inc.
• Lumibird (Quantel Medical)
• Theralase Technologies Inc.
• Photocure ASA
• Biolitec AG
• IPG Photonics Corporation

Definition: Photodynamic therapy (PDT) is a medical treatment that involves the use of a photosensitive drug and specific wavelengths of light to selectively target and destroy abnormal cells, such as cancer cells or certain skin conditions, while minimizing damage to surrounding healthy tissues.